QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 contact-lens-supplier-bausch--lomb-eyes-sale-amid-separation-challenges-as-parent-bausch-health-faces-debt-issues

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to...

 bausch--lomb-shares-up-137-ft-reported-on-saturday-co-is-exploring-sale

https://www.ft.com/content/5272ebe0-146c-484c-8ae3-6fb6edc71fbb

 needham-reiterates-hold-on-bausch--lomb

Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) with a Hold.

Core News & Articles

https://www.wsj.com/articles/bausch-plan-to-spin-off-eye-care-business-stuck-in-creditor-standoff-00e49ff8

 rbc-capital-reiterates-outperform-on-bausch--lomb-maintains-20-price-target

RBC Capital analyst Douglas Miehm reiterates Bausch & Lomb (NYSE:BLCO) with a Outperform and maintains $20 price target.

 hc-wainwright--co-maintains-buy-on-bausch--lomb-lowers-price-target-to-19

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and lowers the price target from ...

 deutsche-bank-maintains-hold-on-bausch--lomb-raises-price-target-to-18

Deutsche Bank analyst Pito Chickering maintains Bausch & Lomb (NYSE:BLCO) with a Hold and raises the price target from $...

Core News & Articles

RBC Capital analyst Douglas Miehm reiterates Bausch & Lomb (NYSE:BLCO) with a Outperform and maintains $20 price target.

 needham-reiterates-hold-on-bausch--lomb

Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) with a Hold.

 tech-stocks-on-track-for-best-session-in-5-months-ahead-of-fed-meeting-small-caps-target-highest-close-since-january-2022-whats-driving-markets-wednesday

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...

 wall-street-remains-on-track-for-amd-led-rebound-ahead-of-fed-decision-meta-earnings-analyst-says-the-bull-tends-to-remain-despite-near-term-volatility

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...

 bausch--lomb-forecasts-2024-revenues-of-470b-480b-versus-prior-guidance-of-460b-470b-and-consensus-of-4661b-with-adjusted-ebitda-of-850m-900m-compared-to-prior-guidance-of-840m890m

2024 Financial Outlook2 Bausch + Lomb raised revenue and Adjusted EBITDA (non-GAAP)1 guidance for the full year of 2024 as fol...

 apple-amazon-microsoft-meta-lead-the-charge-as-investors-bank-on-tech-cheer-for-rallys-reacceleration-week-ahead-in-earnings

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say followin...

 raymond-james-initiates-coverage-on-bausch--lomb-with-outperform-rating-announces-price-target-of-19

Raymond James analyst Gary Nachman initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announce...

 evercore-isi-group-maintains-in-line-on-bausch--lomb-raises-price-target-to-155

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and raises the price target fr...

 why-is-clearside-biomedical-stock-gaining-today

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer ra...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION